April 2018
Price: £95 PLUS VAT
Format: DOWNLOADABLE PDF
This seminar was an opportunity to discuss progress and next steps for the Life Sciences Strategy for Scotland (LSSS) and priorities more widely for supporting Scotland’s life sciences industry.
Delegates discussed the potential impact of the Montgomery Review for Scotland’s life sciences sector in relation to new medicines approval and the establishment of a single national formulary.
Further sessions looked at policy priorities needed to boost innovation, collaboration and the adoption of new technologies. In particular discussion focused on the need for improved data sharing within the life science sector.
Attendees also considered the implications of Brexit on the pharmaceutical and healthcare technology sectors in terms of regulation, investment and the workforce, as well as the work of Scottish Enterprise in supporting Scottish life science firms to build strategic relationships and access new markets post-Brexit.
